KMDA Stock Overview
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics.
Kamada Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₪21.05|
|52 Week High||₪23.23|
|52 Week Low||₪13.09|
|1 Month Change||14.46%|
|3 Month Change||2.18%|
|1 Year Change||33.23%|
|3 Year Change||0.72%|
|5 Year Change||16.62%|
|Change since IPO||60.08%|
Recent News & Updates
Is Kamada (TLV:KMDA) Using Too Much Debt?Jan 26
We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely ReviewedDec 16
Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%Mar 01
Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?Feb 08
Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?Jan 21
Kamada Ltd. (TLV:KMDA) Shares Could Be 42% Below Their Intrinsic Value EstimateJan 03
How Many Kamada Ltd. (TLV:KMDA) Shares Have Insiders Sold, In The Last Year?Dec 15
Are Kamada's (TLV:KMDA) Statutory Earnings A Good Reflection Of Its Earnings Potential?Nov 29
|KMDA||IL Biotechs||IL Market|
Return vs Industry: KMDA exceeded the IL Biotechs industry which returned 15.9% over the past year.
Return vs Market: KMDA exceeded the IL Market which returned -6.7% over the past year.
|KMDA Average Weekly Movement||6.5%|
|Biotechs Industry Average Movement||6.8%|
|Market Average Movement||5.8%|
|10% most volatile stocks in IL Market||9.5%|
|10% least volatile stocks in IL Market||4.0%|
Stable Share Price: KMDA is not significantly more volatile than the rest of IL stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: KMDA's weekly volatility (6%) has been stable over the past year.
About the Company
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD.
Kamada Ltd. Fundamentals Summary
|KMDA fundamental statistics|
Is KMDA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KMDA income statement (TTM)|
|Cost of Revenue||US$95.16m|
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
|Earnings per share (EPS)||0.11|
|Net Profit Margin||4.07%|
How did KMDA perform over the long term?See historical performance and comparison